Navigation Links
Anesiva Announces Expansion of Zingo Agreement in Europe
Date:5/1/2008

SOUTH SAN FRANCISCO, Calif., May 1 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced the expansion of the company's license and distribution agreement for Zingo(TM) with Sigma-Tau SpA to include additional European countries. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system is approved in the United States to provide topical local analgesia prior to peripheral IV insertions or blood draws in children three to 18 years of age.

Under the expanded agreement, Sigma-Tau now has exclusive rights to market and distribute Zingo in all major European markets, excluding the British Isles and the Scandinavian countries. Terms of the expanded agreement include additional upfront payments to Anesiva and transfer price, as well as a milestone payment.

"The expansion of this agreement reflects enthusiasm about the global potential for Zingo to provide quick-onset, needle-free analgesia prior to peripheral venous access procedures in children," said Samantha R. Miller, Anesiva's vice president, business development. "Since the initial agreement was signed in February 2008, Sigma-Tau has made significant progress in defining the regulatory pathway to support commercialization of Zingo in the licensed countries."

About Zingo(TM)

Zingo(TM) is an easy-to-administer, single-use, needle-free system that delivers sterile lidocaine powder to provide topical, local anesthesia to reduce the pain associated with peripheral IV insertions or blood draws. Zingo's rapid onset of action allows intravenous line placement or venipuncture to begin one to three minutes after administration. Zingo is approved in the U.S. to reduce the pain associated with peripheral IV insertions or blood draws i
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Announces New Zingo Marketing and Distribution Agreement
2. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
3. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
4. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
5. Anesiva Appoints Daniel Janney to Board of Directors
6. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
7. Anesiva Announces Completion of Common Stock Offering
8. Anesiva Raises $45 Million in Common Stock Offering
9. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
10. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
11. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
(Date:7/24/2014)... 2014   Cypher Genomics, Inc., the ... Adam Simpson as president and chief ... comprehensive annotation and interpretation of individual human genomes ... "Cypher,s technology has the potential to play a ... accuracy, optimizing therapeutic approaches and reducing adverse drug ...
(Date:7/23/2014)... Arab Emirates (UAE) (PRWEB) July 23, 2014 ... Century recently announced that its biobanking project, ... , Ph.D. to its growing Advisory Board. Scott ... very pleased to have Dr. Vaught onboard with Provia’s ... depth and expertise that Provia’s management team brings to ...
(Date:7/23/2014)... Dresden-Rossendorf (HZDR), the Vienna University of Technology and ... embedding nearly perfect semiconductor crystals into a silicon ... nanowires, very fast and multi-functional processing units can ... future. The research results will be published in ... are considered the cornerstone of future chip technology, ...
Breaking Biology Technology:Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4A crystal wedding in the nanocosmos 2
... NEOG ) announced today that despite obstacles ... revenues increased 11% to $27,840,000, a record third quarter ... $25,180,000. Year-to-date, nine-month revenues rose 17% in the current ... Year-to-date net income for the first nine ...
... Strengthen Expertise in Immunotherapy of CancerBETHESDA, Md., March ... ), a biopharmaceutical company developing novel, proprietary antibodies ... diseases, today announced the the appointment of Sir ... antibody advisory panel. Other members of the company,s ...
... Company estimates sales of pixantrone, if approved, could potentially ... Philips, President of Cell Therapeutics, Inc. (CTI) (NASDAQ and ... the 8th Annual WBBA Invest Northwest Conference on Wednesday, ... CTI,s pixantrone program for treatment of aggressive relapsed non-Hodgkin,s ...
Cached Biology Technology:Neogen Reports Record Third Quarter 2Neogen Reports Record Third Quarter 3Neogen Reports Record Third Quarter 4Neogen Reports Record Third Quarter 5Neogen Reports Record Third Quarter 6Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 2Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 3Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 4Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics 5Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference 2Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference 3
(Date:7/24/2014)... the product of 3.5 billion years of evolutionary trial ... life. But it may be reaching a tipping point. ... analysis of data published in Science , an ... decline of animals is contributing to what appears to ... biological extinction event. , Since 1500, more than 320 ...
(Date:7/24/2014)... A multi-institutional team of researchers has developed a new ... safe, noninvasive method for assessing the function and properties ... to better diagnosis and treatment of gut diseases. ... irritable bowel syndrome and inflammatory bowel disease all occur ... effects in patients with diseases such as diabetes and ...
(Date:7/24/2014)... affect the connections between nerve cells and influence the ... of the brain that plays a significant role in ... of the study have been published in the journal ... active communication between nerve cells, known as neurons. For ... network where they constantly relay signals to one another. ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3New imaging agent provides better picture of the gut 2A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4
... of chemists from the University of Valencia (UV) has ... amphora found among remains at Lixus, in Morocco, was ... inside the 2,000-year-old vessel, which could be fragments of ... of archaeologists from the UV discovered a sealed amphora ...
... Although they are present almost everywhere, on land ... the superphylum Planctomycetes-Verrucomicrobia-Chlamydiae, or PVC, have remained in ... about a decade ago. Scientists at the European ... discovered that these poorly-studied bacteria possess proteins thought ...
... The Genetics Society of America is pleased to announce ... for Professional Development in Genetics. These travel ... and international meetings or enroll in laboratory courses. ... DeLill Nasser (1929-2000), who was instrumental in promoting genetics ...
Cached Biology News:Chemical analyses uncover secrets of an ancient amphora 2Membrane-coat proteins: Bacteria have them too 2
... Synaptogyrin 2 ( Abpromise ... Antigen: Synthetic ... sequence amino acids 42-57 of ... Entrez Gene ID: ...
Rabbit polyclonal to SMURF 2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide (10-30 aa in length) at the N-term of first 50 aa of human SMURF 2. Entrez G...
Rabbit polyclonal antibody to NCOA2 [Agarose Immobilized]...
Rabbit anti Mouse ZIC2 Preservative: NaN3...
Biology Products: